- Home
- RXO vs GLPG Comparison
RXO vs GLPG Comparison
Compare RXO & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RXO | GLPG |
|---|---|---|
| Founded | 2022 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | RXO | GLPG |
|---|---|---|
| Price | $13.69 | $33.03 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 15 | 4 |
| Target Price | $16.25 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 2.1M | 99.7K |
| Earning Date | 02-06-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,940,000,000.00 | $336,643,201.00 |
| Revenue This Year | $28.02 | $1.76 |
| Revenue Next Year | $3.31 | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.85 | 10.31 |
| 52 Week Low | $10.43 | $22.36 |
| 52 Week High | $26.92 | $37.78 |
Technical Indicators
Market Signals| Indicator | RXO | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 50.49 | 58.73 |
| Support Level | $12.45 | $32.33 |
| Resistance Level | $14.65 | $33.91 |
| Average True Range (ATR) | 0.60 | 0.70 |
| MACD | 0.11 | 0.03 |
| Stochastic Oscillator | 58.62 | 61.92 |
Price Performance
Historical ComparisonAbout RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.